David L Russell-Jones (David Russell-Jones, D L Russell-Jones)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 17

Top Topics

Cardiovascular Disease

Glycemic Control

Top Venues

Diabetes, obesity & metabolism

Diabetic medicine : a journal of the British Diabetic Association

This page only lists publications with an associated author ORCID identifier.

Publications

David L Russell-Jones, Timothy S Bailey, Wendy Lane, Chantal Mathieu, Ulrik Pedersen-Bjergaard
Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal-bolus insulin regimens in treat-to-target trials: A narrative review. Diabetic medicine : a journal of the British Diabetic Association (2024)
David L Russell-Jones, Timothy S Bailey, Wendy Lane, Chantal Mathieu, Ulrik Pedersen-Bjergaard
Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal-bolus insulin regimens in treat-to-target trials: A narrative review. Diabetic medicine : a journal of the British Diabetic Association 41 (7) (2024)
David L Russell-Jones, Timothy S Bailey, Wendy Lane, Chantal Mathieu, Ulrik Pedersen-Bjergaard
Frequency of hypoglycaemia with basal insulin treatments in adults with type 1 diabetes treated with basal-bolus insulin regimens in treat-to-target trials: A narrative review. Diabetic medicine : a journal of the British Diabetic Association 41 (7) (2024)
Athena Philis-Tsimikas, Harpreet S Bajaj, Kamilla Begtrup, Roman Cailleteau, Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David L Russell-Jones, Julio Rosenstock
Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. Diabetes, obesity & metabolism (2022)
Roselle A Herring, Fariba Shojaee-Moradie, Mary Stevenage, Iain Parsons, Nicola Jackson, Jeewaka Mendis, Benita Middleton, A Margot Umpleby, Barbara A Fielding, Melanie Davies, David L Russell-Jones
The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes. Diabetes care 45 (6) (2022)
David L Russell-Jones, Ewan J Hutchison, Graham A Roberts
Pilots flying with insulin-treated diabetes. Diabetes, obesity & metabolism 23 (7) (2021)
Roselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A Fielding, Agampodi Mendis, Sigurd Johnsen, A Margot Umpleby, Melanie Davies, David L Russell-Jones
Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136. Diabetes care 44 (3) (2021)
Melanie Jane Davies, Julio Rosenstock, Amar Ali, David L Russell-Jones, Elisabeth Souhami, Karen Palmer, Chen Ji, Elisabeth Niemoeller, Neil Skolnik
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial. Diabetes, obesity & metabolism 24 (1) (2021)
Gillian L Garden, Brian M Frier, Julia L Hine, Ewan J Hutchison, Stuart J Mitchell, Kenneth M Shaw, Simon R Heller, Gerd Koehler, Veronika Hofmann, Thomas P Gaffney, Declan Maher, Graham A Roberts, David L Russell-Jones
Blood glucose monitoring by insulin-treated pilots of commercial and private aircraft: An analysis of out-of-range values. Diabetes, obesity & metabolism 23 (10) (2021)
David L Russell-Jones, Roselle A Herring
100 years of physiology, discrimination and wonder. Diabetic medicine : a journal of the British Diabetic Association 38 (12) (2021)
Gillian L Garden, Julia L Hine, Stuart J Mitchell, Ewan J Hutchison, Thomas P Gaffney, Veronika Hofmann, Brian M Frier, Kenneth M Shaw, Simon R Heller, Gerd Koehler, Graham A Roberts, David L Russell-Jones
An Evaluation of the Safety of Pilots With Insulin-Treated Diabetes in Europe Flying Commercial and Noncommercial Aircraft. Diabetes care 43 (12) (2020)
Roselle A Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A Fielding, Agampodi Mendis, Sigurd Johnsen, A Margot Umpleby, Melanie Davies, David L Russell-Jones
Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes care 43 (9) (2020)
David L Russell-Jones, B M Frier, K M Shaw
USA joins Canada, UK, Ireland and Austria in allowing people with insulin-treated diabetes to fly commercial aircraft. Diabetic medicine : a journal of the British Diabetic Association 37 (7) (2020)
David L Russell-Jones, Arnaud Dauchy, Elías Delgado, George Dimitriadis, Hans A Frandsen, Luiza Popescu, Bernd Schultes, Krzysztof Strojek, Mireille Bonnemaire, Aude Roborel de Climens, Melanie Jane Davies
Take Control: A randomized trial evaluating the efficacy and safety of self- versus physician-managed titration of insulin glargine 300 U/mL in patients with uncontrolled type 2 diabetes. Diabetes, obesity & metabolism 21 (7) (2019)
Melanie Jane Davies, David L Russell-Jones, Thomas M Barber, Fernando J Lavalle-González, Gagik R Galstyan, Dalong Zhu, Mike Baxter, Cecile Dessapt-Baradez, Rory J McCrimmon
Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial. Diabetes, obesity & metabolism 21 (8) (2019)
Bruce W Bode, Keith Bowering, David L Russell-Jones
Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957. Diabetes care 41 (3) (2018)
David L Russell-Jones, Bruce W Bode, Christophe De Block, Edward Franek, Simon R Heller, Chantal Mathieu, Athena Philis-Tsimikas, Ludger Rose, Vincent C Woo, Anne Birk Østerskov, Tina Graungaard, Richard M Bergenstal
Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). Diabetes care 40 (7) (2017)